Early postoperative results from the Preoperative Octreotide Treatment of Acromegaly (POTA) study has been published previously (1), and like later randomized studies we demonstrated a beneficial effect of presurgical treatment with somatostatin analogues (SSA) in GH-secreting macroadenomas when evaluated 3-4 months postoperatively.
Five years following operation, the cure rate in the pretreatment group was 41 % in total and 40 % in macroadenomas, versus 31 % and 27 % in the direct surgery group, respectively (Table 3) . There was no significant difference between the treatment groups. Table 3 . Cure rates at 5 years postoperative Table 2 . Cure rates at 1 year postoperative P r eo pe r ativ e S SA (n=3 1) D ir e ct sur g er y (n = 3 0 ) 
RESULTS
The proportion of patients receiving postoperative acromegaly treatment was equal in the two groups both one (Table 1) and five years postoperatively. 
CONCLUSION
These long-term data from the POTA study does not prove a beneficial effect of SSA presurgical treatment. However, in absolute numbers and in accordance with 3 months postoperative data from the POTA study, an approximately 50 % increase in cure rate is found for macroadenomas. Accordingly, we can not exclude that this is due to lack of power. 
